Form 8-K - Current report:
SEC Accession No. 0000950170-22-015582
Filing Date
2022-08-08
Accepted
2022-08-08 16:41:14
Documents
14
Period of Report
2022-08-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K clsd-20220808.htm   iXBRL 8-K 73751
2 EX-99.1 clsd-ex99_1.htm EX-99.1 36872
3 GRAPHIC img171462827_0.jpg GRAPHIC 6360
  Complete submission text file 0000950170-22-015582.txt   246229

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT clsd-20220808_pre.xml EX-101.PRE 9843
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT clsd-20220808.xsd EX-101.SCH 2469
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT clsd-20220808_lab.xml EX-101.LAB 13352
8 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20220808_htm.xml XML 4717
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37783 | Film No.: 221145018
SIC: 2834 Pharmaceutical Preparations